Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 February 2006, Vol. 107, No. 3, pp. 1018-1023.
Prepublished online as a Blood First Edition Paper on October 6, 2005; DOI 10.1182/blood-2005-07-3032.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-07-3032v1
107/3/1018    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coenen, J. J. A.
Right arrow Articles by Joosten, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coenen, J. J. A.
Right arrow Articles by Joosten, I.
Related Collections
Right arrow Transplantation
Right arrow Immunobiology
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

IMMUNOBIOLOGY

Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells

Jeroen J. A. Coenen, Hans J. P. M. Koenen, Esther van Rijssen, Luuk B. Hilbrands, and Irma Joosten

From the Department of Bloodtransfusion and Transplantation Immunology and the Department of Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

The immunosuppressive drugs rapamycin and cyclosporin A (CsA) are widely used to prevent allograft rejection. Moreover, they were shown to be instrumental in experimental models of tolerance induction. However, it remains to be elucidated whether these drugs have an effect on the CD4+CD25+ regulatory T-cell (TREG) population, which plays an important role in allograft tolerance. Recently, we reported that alloantigen-driven expansion of human CD4+CD25+ TREGs gives rise to a distinct highly suppressive CD27+TREG subset next to a moderately suppressive CD27-TREG subset. In the current study we found that rapamycin and CsA do not interfere with the suppressive activity of human naturally occurring CD4+CD25+ T cells. However, in contrast to CsA, rapamycin preserved the dominance of the potent CD27+TREG subset over the CD27-TREG subset after alloantigen-driven expansion of CD4+CD25+ TREGs in vitro. Accordingly, CD4+CD25+ TREGs cultured in the presence of rapamycin displayed much stronger suppressive capacity than CD4+CD25+ TREGs cultured in the presence of CsA. In addition, CD4+CD25+ TREG cells cultured in the presence of rapamycin, but not CsA, were able to suppress ongoing alloimmune responses. This differential effect of rapamycin and CsA on the CD27+TREG subset dominance may favor the use of rapamycin in tolerance-inducing strategies.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
H. R. Turnquist, T. L. Sumpter, A. Tsung, A. F. Zahorchak, A. Nakao, G. J. Nau, F. Y. Liew, D. A. Geller, and A. W. Thomson
IL-1{beta}-Driven ST2L Expression Promotes Maturation Resistance in Rapamycin-Conditioned Dendritic Cells
J. Immunol., July 1, 2008; 181(1): 62 - 72.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
J. Kang, S. J. Huddleston, J. M. Fraser, and A. Khoruts
De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR
J. Leukoc. Biol., May 1, 2008; 83(5): 1230 - 1239.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Basu, T. Golovina, T. Mikheeva, C. H. June, and J. L. Riley
Cutting Edge: Foxp3-Mediated Induction of Pim 2 Allows Human T Regulatory Cells to Preferentially Expand in Rapamycin
J. Immunol., May 1, 2008; 180(9): 5794 - 5798.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y.-H. Lee, Y.-R. Lee, S.-A Im, S.-I. Park, K.-H. Kim, T. Gerelchuluun, S. Song, K. Kim, and C.-K. Lee
Calcineurin Inhibitors Block MHC-Restricted Antigen Presentation In Vivo
J. Immunol., November 1, 2007; 179(9): 5711 - 5716.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. R. Turnquist, G. Raimondi, A. F. Zahorchak, R. T. Fischer, Z. Wang, and A. W. Thomson
Rapamycin-Conditioned Dendritic Cells Are Poor Stimulators of Allogeneic CD4+ T Cells, but Enrich for Antigen-Specific Foxp3+ T Regulatory Cells and Promote Organ Transplant Tolerance
J. Immunol., June 1, 2007; 178(11): 7018 - 7031.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
B. D. CARSON and S. F. ZIEGLER
Impaired T Cell Receptor Signaling in Foxp3+ CD4 T Cells
Ann. N.Y. Acad. Sci., April 1, 2007; 1103(1): 167 - 178.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Strauss, T. L. Whiteside, A. Knights, C. Bergmann, A. Knuth, and A. Zippelius
Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin
J. Immunol., January 1, 2007; 178(1): 320 - 329.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Kreijveld, H. J. P. M. Koenen, L. B. Hilbrands, H. J. P. van Hooff, and I. Joosten
The immunosuppressive drug FK778 induces regulatory activity in stimulated human CD4+CD25- T cells
Blood, January 1, 2007; 109(1): 244 - 252.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Battaglia, A. Stabilini, B. Migliavacca, J. Horejs-Hoeck, T. Kaupper, and M.-G. Roncarolo
Rapamycin Promotes Expansion of Functional CD4+CD25+FOXP3+ Regulatory T Cells of Both Healthy Subjects and Type 1 Diabetic Patients
J. Immunol., December 15, 2006; 177(12): 8338 - 8347.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Rezvani, S. Mielke, M. Ahmadzadeh, Y. Kilical, B. N. Savani, J. Zeilah, K. Keyvanfar, A. Montero, N. Hensel, R. Kurlander, et al.
High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT
Blood, August 15, 2006; 108(4): 1291 - 1297.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Zeiser, V. H. Nguyen, A. Beilhack, M. Buess, S. Schulz, J. Baker, C. H. Contag, and R. S. Negrin
Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production
Blood, July 1, 2006; 108(1): 390 - 399.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020